Hubungan Polimorfisme ABCB1 C3435T Dengan Derajat Neutropenia Pada Pasien Kanker Payudara yang Mendapat Kemoterapi Mengandung Regimen Doksorubisin-Taksan
DAFTAR PUSTAKA
ACS. (2011). Breast Cancer What is cancer ?(pp. 1–134).
Ambudkar, S. V, Kimchi-Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003).
P-glycoprotein: from genomics to mechanism. Oncogene, 22(47), 7468–85.
doi:10.1038/sj.onc.1206948
Amerongen, R. Van, & Berns, A. (2006). TXR1-mediated thrombospondin
repression : a novel mechanism of resistance to taxanes ? Genes &
Development, 20, 1975–1981. doi:10.1101/gad.1460806
Ameyaw M M, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. (2001).
ABCB1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is
significantly influenced by ethnicity. Pharmacogenetics, 11, 217-221
Albrektsen, G., Heuch, I. & Thoresen, S.Ø., (2010). Histological type and grade
of breast cancer tumors by parity, age at birth, and time since birth: a
register-based study in Norway. BMC cancer , 10, 226.
Ashariati, A., (2008). Polymorphism C3435T of The MDR-1 Gene Predict
Response to Preoperative Chemotherapy in Locally Advanced Breast Cancer
with Her2 / neu Expression. Acta Med Indones-Indones J Inter Med , 40(4),
187–191.
Balram, C. et al., (2003). Frequency of C3435T single nucleotide MDR1 genetic
polymorphism in an Asian population : phenotypic – genotypic correlates.
Br J Clin Pharmacol, 56, 78–83.
Bartoszek, A. (2002). Metabolic activation of adriamycin by NADPH-cytochrome
P450 reductase ; overview of its biological and. Acta Biochimica Polonica ,
49(2), 323–331.
Biemans-Oldehinkel, E., Doeven, M. K., & Poolman, B. (2006). ABC transporter
architecture and regulatory roles of accessory domains. FEBS Letters,
580(4), 1023–35
Bressolle, F., Jacquet, J., Galtier, M., Jourdan, J., & Donadio, D. (1992).
Doxorubicin and doxorubicinol plasma concentrations and excretion in
parotid saliva. Cancer Chemother Pharmacol, 30, 215–218.
Buchholz, T. a, Stivers, D. N., Stec, J., Ayers, M., Clark, E., Bolt, A., … Pusztai,
L. (2002). Global gene expression changes during neoadjuvant chemotherapy
for human breast cancer. Cancer Journal (Sudbury, Mass.), 8(6), 461–8.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12500855
Universitas Sumatera Utara
Calado, R. T., Falcao, R. P., Garcia, A. B., & Gabellini, S. M. (2002). Influence of
functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34
hematopoietic stem cells. Haematologica , 87(6), 564–568.
Callies, S., de Alwis, D. P., Wright, J. G., Sandler, A., Burgess, M., & Aarons, L.
(2003). A population pharmacokinetic model for doxorubicin and
doxorubicinol in the presence of a novel MDR modulator, zosuquidar
trihydrochloride (LY335979). Cancer Chemotherapy and Pharmacology,
51(2), 107–18. doi:10.1007/s00280-002-0542-3
Cascorbi, I. (2006). Role of pharmacogenetics of ATP-binding cassette
transporters in the pharmacokinetics of drugs. Pharmacology &
Therapeutics, 112, 457–473. doi:10.1016/j.pharmthera.2006.04.009
Chang, H., Rha, S. Y., Jeung, H., Im, C., Ahn, J. B., Kwon, W. S., … Chung, H.
C. (2008). Association of the ABCB1 gene polymorphisms 2677G > T / A
and 3435C > T with clinical outcomes of paclitaxel monotherapy in
metastatic breast cancer patients. Annals of Oncology, 2677, 1–6.
doi:10.1093/annonc/mdn624
Chargari, C., Kirov, K. M., Bollet, M. a, Magné, N., Védrine, L., Cremades, S., …
Kirova, Y. M. (2011). Cardiac toxicity in breast cancer patients: from a
fractional point of view to a global assessment. Cancer Treatment Reviews,
37(4), 321–30. doi:10.1016/j.ctrv.2010.08.007
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin
cardiomyopathy. Cardiology, 115(2), 155–62. doi:10.1159/000265166
Cizmarikova, M., Wagnerova, M., Schonova, L., Habalova, V., Kohut, A.,
Linkova, A., … Mirossay, L. (2009). MDR1 ( C3435T ) polymorphism :
relation to the risk of breast cancer and therapeutic outcome. The
Pharmacogenomics Journal, 10(1), 62–69. doi:10.1038/tpj.2009.41
Crawford, J., Dale, D. C., Lyman, G. H., & Crawford, C. N. (2004).
Chemotherapy-Induced Neutropenia, 228–237. doi:10.1002/cncr.11882
CTCAE, C. T. C. for A. E. (2010). Common Terminology Criteria for Adverse
Events ( CTCAE ). Publish (Vol. 2009, pp. 0–71). National Cancer Institute,
Cancer Therapy Evaluation Program.
Danesi, R., Fogli, S., Gennari, A., Conte, P., & Tacca, M. Del. (2002).
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline
Anticancer Drugs. Clin Pharmacokinet, 41(6), 431–444.
Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance.
Nature Reviews. Cancer , 5(4), 275–84. doi:10.1038/nrc1590
Universitas Sumatera Utara
Erdélyi, D.J. et al., (2006). The role of ABC-transporter gene polymorphisms in
chemotherapy induced immunosuppression, a retrospective study in
childhood acute lymphoblastic leukaemia. Cellular immunology, 244(2),
121–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17434155
[Accessed November 26, 2014].
Evans, T. R. J., Yellowlees, A., Foster, E., Earl, H., Cameron, D. a, Hutcheon, A.
W., … Mansi, J. L. (2005). Phase III randomized trial of doxorubicin and
docetaxel versus doxorubicin and cyclophosphamide as primary medical
therapy in women with breast cancer: an anglo-celtic cooperative oncology
group study. Journal of Clinical Oncology : Official Journal of the
American
Society
of
Clinical
Oncology,
23(13),
2988–95.
doi:10.1200/JCO.2005.06.156
Fajac, A., Gligorov, J., Rezai, K., Levy, P., Levy, E., Selle, F., … Lokiec, F.
(2010). Effect of ABCB1 C3435T polymorphism on docetaxel
pharmacokinetics according to menopausal status in breast cancer patients,
560–566. doi:10.1038/sj.bjc.6605789
Franke, R. M., Gardner, E. R., & Sparreboom, A. (2010). Pharmacogenetics of
Drug Transporters. Current Pharmaceutical Design , 16, 220–230.
Fung, K. L., & Gottesman, M. M. (2009). A synonymous polymorphism in a
common MDR1 (ABCB1) haplotype shapes protein function. Biochimica et
Biophysica Acta , 1794(5), 860–71. doi:10.1016/j.bbapap.2009.02.014
Garattini, S. (2006). Pharmacokinetics
doi:10.1016/j.ejca.2006.10.015
in
cancer
chemotherapy,
3.
Gasparini, G., Longo, R., Torino, F., Gattuso, D., Morabito, A., & Toffoli, G.
(2006). Is tailored therapy feasible in oncology ? Critical Reviews in
Oncology/Hematology, 57, 79–101. doi:10.1016/j.critrevonc.2005.07.003
Gewirtz, D. A. (1999). A Critical Evaluation of the Mechanisms of Action
Proposed for the Antitumor Effects of the Anthracycline Antibiotics
Adriamycin and Daunorubicin. Biochemical Pharmacology, 57(98), 727–
741.
Gillet, J., Efferth, T., & Remacle, J. (2007). Chemotherapy-induced resistance by
ATP-binding
cassette
transporter
genes,
1775,
237–262.
doi:10.1016/j.bbcan.2007.05.002
Gligorov, J., & Lotz, J. P. (2004b). Preclinical pharmacology of the taxanes:
implications of the differences. The Oncologist, (suppl 2), 3–8. Retrieved
from http://www.ncbi.nlm.nih.gov/pubmed/15161985
Universitas Sumatera Utara
Goldhirsch, A., Glick, J. H., Gelber, R. D., & Coates, A. S. (2001). Meeting
Highlights : International Consensus Panel on the Treatment of Primary
Breast Cancer. Journal of Clinical Oncology, 19(18), 3817–3827.
Goto, S., Ihara, Y., Urata, Y., Izumi, S., Abe, K., Koji, T., & Kondo, T. (2001).
Doxorubicin-induced DNA intercalation and scavenging by nuclear
glutathione S-transferase pi. FASEB Journal : Official Publication of the
Federation of American Societies for Experimental Biology, 15(14), 2702–
14. doi:10.1096/fj.01-0376com
Gottesman, M. M. (2002). Mechanisms of Cancer Drug Resistance.
Annu.Rev.Med,
53,
615–27.
Retrieved
from
http://www.medicine.wisc.edu/~williams/drugresistance.pdf
Gustafson, D. L., & Page, R. L. (2013). Cancer Chemotherapy. Withrow and
MacEwen’s Small Animal Clinical Oncology, 5/e (Fifth Edit., pp. 157–179).
Elsevier Inc. doi:10.1016/B978-1-4377-2362-5.00011-6
Gwak, G., Kim, J.-Y., Park, K., Shin, Y. J., Cho, H., Park, S. J., … Han, S.
(2011). Comparison of Doxorubicin plus docetaxel neoadjuvant
chemotherapy with Doxorubicin plus vinorelbine in primary breast cancer. J
Breast Cancer , 14(2), 129–34. doi:10.4048/jbc.2011.14.2.129
Huang, Y. (2007). Pharmacogenetics/genomics of membrane transporters in
cancer chemotherapy. Cancer Metastasis Reviews, 26(1), 183–201.
doi:10.1007/s10555-007-9050-6
Henderson, I.C. et al., (2003). Improved Outcomes From Adding Sequential
Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant
Chemotherapy Regimen for Patients With Node-Positive Primary Breast
Cancer. Journal of Clinical Oncology, 21(6), pp.976–983.
Ih, A. (2013). A Review on Aetio-Pathogenesis of Breast Cancer. J Genet Syndr
Gene Ther , 4(5), 1–4. doi:10.4172/2157-7412.1000142
Joerger, M., Huitema, a D. R., Meenhorst, P. L., Schellens, J. H. M., & Beijnen, J.
H. (2005). Pharmacokinetics of low-dose doxorubicin and metabolites in
patients with AIDS-related Kaposi sarcoma. Cancer Chemotherapy and
Pharmacology, 55(5), 488–96. doi:10.1007/s00280-004-0900-4
Katzung, B. (2003). Chapter 55: Cancer chemotherapy. In Basic & Clinical
Pharmacology (pp. 1281–1290).
Kimchi-sarfaty, C. et al., (2007). A “Silent” Polymorphism in the MDR1 Gene
Changes Substrate Specificity. SCIENCE , 315, pp.525–527.
Universitas Sumatera Utara
Kroetz, D.L. et al., (2003). Sequence diversity and haplotype structure in the
human ABCB1 ( MDR1 , multidrug resistance transporter ) gene.
Pharmacogenetics, 13, pp.481–494.
Kudzi, W., Dodoo, A.N.O. & Mills, J.J., (2010). Genetic polymorphisms in
MDR1 , CYP3A4 and CYP3A5 genes in a Ghanaian population : a
plausible explanation for altered metabolism of ivermectin in humans ?
BMC Medical Genetics, 11, p.111.
Lam, P. et al., (2000). The Association of Increased Weight , Body Mass Index ,
and Tissue Density with the Risk of Breast Carcinoma in Vermont.
CANCER, 89(2), pp.370–74.
Lalami, Y., Paesmans, M., Muanza, F., Barette, M., Plehiers, B., Dubreucq, L., …
Klastersky, J. (2006). Can we predict the duration of chemotherapy-induced
neutropenia in febrile neutropenic patients , focusing on regimen-specific
risk factors ? A retrospective analysis. Annals of Oncology, 17(December
2005), 507–514. doi:10.1093/annonc/mdj092
Lazo, J. S., & Schwartzt, P. E. (1985). Rapid Distribution of Adriamycin in the
Ascitic and Pleural Fluid of Women with Ovarian Carcinomas. Gynecologic
Oncology, 21, 65–72.
Lei, H., Wang, X., & Wu, C. (2012). Early stage intercalation of doxorubicin to
DNA fragments observed in molecular dynamics binding simulations.
Journal of Molecular
Graphics & Modelling, 38, 279–89.
doi:10.1016/j.jmgm.2012.05.006
Mary Ameyaw, M., & McLeod, H. L. (2006). Improving The Efficacy And Safety
Of Anticancer Agents-The Role Of Pharmacogenetics. Novel Anticancer
Agents.
McCarthy, A.R., (2006). Biological Activity of Steroid Analogues: Synthesis and
Receptor/Enzyme Interactions. University of Canterbury
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004).
Anthracyclines : Molecular Advances and Pharmacologic Developments in
Antitumor Activity and Cardiotoxicity. Pharmacol Rev, 56(2), 185–229.
doi:10.1124/pr.56.2.6.185
Monneret, C. (2001). Recent developments in the field of antitumour
anthracyclines. Eur.J.Med.Chem, 36, 483–493.
Moss, G. (1997). Breast cancer. In F. S. Bongard, M. J. Stamos, & E. Passaro
(Eds.), Surgery: A Clinical Approach (first., pp. 273–278). New York:
Churchill Livingstone.
Universitas Sumatera Utara
Morris, C. et al., 2009. Trends in Cancer Incidence , Mortality , Risk Factors ,
Health Behaviors in California. In Cancer Surveillance section . pp. 17–19.
Ostad, S. N., & Parsa, M. (2011). Breast Cancer from Molecular Point of View :
Pathogenesis and Biomarkers. In M. Gunduz & E. Gunduz (Eds.), Breast
Cancer-Focusing Tumor Microenvironment, Stem Cells and Metastasis (1st
ed., pp. 103–121). Tehran: InTech.
Oswald, S., Grube, M., Siegmund, W., & Kroemer, H. K. (2007). Transportermediated uptake into cellular compartments. Xenobiotica; the Fate of
Foreign Compounds in Biological Systems , 37(10-11), 1171–95.
doi:10.1080/00498250701570251
Panaretakis, T., Laane, E., Pokrovskaja, K., Bjo, A., Moustakas, A., Zhivotovsky,
B., … Grande, D. (2005). Doxorubicin Requires the Sequential Activation of
Caspase-2 , Protein Kinase C , and c-Jun NH 2 -terminal Kinase to Induce
Apoptosis , 16(August), 3821–3831. doi:10.1091/mbc.E04
Patel, K. J., & Tannock, I. F. (2009). The influence of P-glycoprotein expression
and its inhibitors on the distribution of doxorubicin in breast tumors. BMC
Cancer , 9, 356. doi:10.1186/1471-2407-9-356
Peterson, C., & Trouet, A. (1978). Transport and Storage of Daunorubicin and
Doxorubicin in Cultured Fibroblasts. Cancer Research, 38, 4645–4649.
Plana, J. C. (2011). Chemotherapy and the Heart. Revista Española de
Cardiología
(English
Edition),
64(5),
409–415.
doi:10.1016/j.rec.2010.12.019
Preobrazhenskaya, M. N., Tevyashova, A. N., & Olsufyeva, E. N. (2006). Second
Generation Drugs-derivatives of Natural Antitumor Anthracycline
Antibiotics Daunorubicin , Doxorubicin and Carminomycin. J Med Sci,
26(4), 119–128.
Puma, N., Ruggiero, A., Ridola, V., Ilaria, M., Giorgio, L., Stefano, A., … Rosa,
G. D. E. (2008). Anthracycline-related cardiotoxicity : risk factors and
therapeutic options in childhood cancers. SIGNAE VITAE , 3(1), 30–34.
Raisch, D. W., Holdsworth, M. T., Winter, S. S., Hutter, J. J., & Graham, M. L.
(2003). Economic Comparison of Home-Care-Based versus Hospital- Based
Treatment of Chemotherapy-Induced Febrile Neutropenia in Children. Value
in Health, 6(2), 158–166. doi:10.1046/j.1524-4733.2003.00219.x
Riddick, D. S., Lee, C., Ramji, S., Chinje, E. C., Cowen, R. L., Williams, K. J., …
Waxman, D. J. (2005). Cancer Chemotherapy And Drug Metabolism. Drug
Metabolism
and
Disposition ,
33(8),
1083–1096.
doi:10.1124/dmd.105.004374.normal
Universitas Sumatera Utara
Robert, J., Morvan, L., Smith, D., Pourquier, P., & Bonnet, J. (2005). Predicting
drug response and toxicity based on gene polymorphisms, 54, 171–196.
doi:10.1016/j.critrevonc.2005.01.005
Rowinsky, E. K. (1997). The development and clinical utility of the taxane class
of antimicrotubule chemotherapy agents. Annu.Rev.Med, 48, 353–74.
doi:10.1146/annurev.med.48.1.353
Rowinsky, E. K. (1997). The development and clinical utility of the taxane class
of antimicrotubule chemotherapy agents. Annu.Rev.Med, 48, 353–74.
doi:10.1146/annurev.med.48.1.353
Rudek, M. a, Sparreboom, A., Garrett-Mayer, E. S., Armstrong, D. K., Wolff, a
C., Verweij, J., & Baker, S. D. (2004). Factors affecting pharmacokinetic
variability following doxorubicin and docetaxel-based therapy. European
Journal of Cancer , 40(8), 1170–8. doi:10.1016/j.ejca.2003.12.026
Schimmel, K., Straaten, T. Van Der, & Bogaartz, J. (n.d.). Doxorubicin And Cpec
Induced Cardioxicity : association with the GTPase gene Rac2 , and drug
transporter genes MRP1 and MRP2.
Schwartz, J. et al., (2005). Evaluation of anemia, neutropenia and skin toxicities in
standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or
docetaxel adjuvant chemotherapy in breast cancer. Annals of oncology,
16(2), pp.247–52.
Sharom, F. J. (2008). ABC multidrug transporters : structure , function and role
in chemoresistance. Pharmacogenomics, 9, 105–127.
Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. P. (2011). Mechanisms
and management of doxorubicin cardiotoxicity. Herz, 36(4), 296–305.
doi:10.1007/s00059-011-3470-3
Simůnek, T., Stérba, M., Popelová, O., Adamcová, M., Hrdina, R., & Gersl, V.
(2009). Anthracycline-induced cardiotoxicity: overview of studies examining
the roles of oxidative stress and free cellular iron. Pharmacological Reports,
61(1),
154–71.
Retrieved
from
http://www.ncbi.nlm.nih.gov/pubmed/19307704
Sissung, T. M., Mross, K., Steinberg, S. M., Behringer, D., Figg, W. D.,
Sparreboom, A., & Mielke, S. (2006). Association of ABCB1 genotypes with
paclitaxel-mediated peripheral neuropathy and neutropenia. European
Journal Of Cancer , 42, 2893–2896. doi:10.1016/j.ejca.2006.06.017
Sledge, G.., (1999). First-Line Chemotherapy for Advancer Breast Cancer.
Journal of The Moffit Cancer Center , 6(5), pp.4–7.
Universitas Sumatera Utara
Smith, K. (2002). Genetic Polymorphism And Snps (Pp. 1–13). Retrieved From
http://grants.nih.gov
Society, A. C. (2011). Breast Cancer.
Sparreboom, A., Danesi, R., Ando, Y., Chan, J., & Figg, W. D. (2003).
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
Drug Resistance Updates, 6, 71–84. doi:10.1016/S1368-7646(03)00005-0
Sugunan, S. L. C. (2008). Pharmacogenetics Of Doxorubicin In Asian Breast
Cancer Patients. National university of Singapore.
Taheri, M., Mahjoubi, F., & Omranipour, R. (2010). Effect of MDR1
polymorphism on multidrug resistance expression in breast cancer patients.
Genet.Mol.Res, 9(1), 34–40.
Tran, A. Et Al., (2006). Pharmacogenetics And Genomics Pharmacokinetics And
Toxicity Of Docetaxel : Role Of CYP3A, MDR1, And GST
Polymorphisms. Clinical Pharmacology & Therapeutc, 79(6), Pp.570–581.
Tan, S., Lee, S., & Goh, B. (2008). Pharmacogenetics in Breast Cancer Therapy
Pharmacogenetics in Breast Cancer Therapy. Clinical Cancer Res, 14, 8027–
8041. doi:10.1158/1078-0432.CCR-08-0993
Tandon, V. R., Kapoor, B., Bano, G., Gupta, S., Gillani, Z., & Kour, D. (2006). Pglycoprotein : Pharmacological relevance relevance. Indian J Pharmacol,
38(1), 13–24.
Thorn, C., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T.,
& Altman, R. (2011). Doxorubicin pathways: pharmacodynamics and
adverse
effects.
Pharmacogenet
Genomics,
21(7),
440–446.
doi:10.1097/FPC.0b013e32833ffb56.Doxorubicin
Tsai, C., Sauna, Z. E., Kimchi-sarfaty, C., Ambudkar, S. V, Gottesman, M. M.,
Nussinov, R., & Aviv, T. (2008). Synonymous Mutations and Ribosome
Stalling Can Lead to Altered Folding Pathways and Distinct Minima.
J.Mol.Biol, 383, 281–291. doi:10.1016/j.jmb.2008.08.012
Turgut, S., Yaren, A., & Kursunluoglu, R. (2007). MDR1 C3435T Polymorphism
in Patients with Breast Cancer. Archives of Medical Research , 38, 539–544.
doi:10.1016/j.arcmed.2007.02.005
Vasiliou, V., Vasiliou, K., & Nebert, D. W. (2009). Human ATP-binding cassette
( ABC ) transporter family. Human Genomics, 3(3), 281–290.
Vávrová, A., Popelová, O., Stěrba, M., Jirkovský, E., Hašková, P., MertlíkováKaiserová, H., … Simůnek, T. (2011). In vivo and in vitro assessment of the
role of glutathione antioxidant system in anthracycline-induced
Universitas Sumatera Utara
cardiotoxicity. Archives of Toxicology, 85(5), 525–35. doi:10.1007/s00204010-0615-8
Vulsteke, C., Lambrechts, D., Dieudonné, A., Hatse, S., Brouwers, B., Brussel, T.
Van, … Wildiers, H. (2013). Genetic variability in the multidrug resistance
associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in
breast cancer patients receiving (neo-)adjuvant chemotherapy with 5fluorouracil, epirubicin and cyclophosphamide (FEC). Annals of Oncology,
1–13. doi:10.1093/annonc/mdt008
Warren, B.S. & Devine, C., (2003). Breast Cancer in Women from Different
Racial / Ethnic Groups. , (April), pp.1–5.
Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Abcb, O. (2005).
Multidrug resistance polypeptide 1 ( MDR1 , ABCB1 ) variant 3435C > T
affects mRNA stability. Pharmacogenetics and Genomics, 15, 693–704.
Westbrook, K., & Stearns, V. (2013). Pharmacology & Therapeutics
Pharmacogenomics of breast cancer therapy : An update Pharmacology and
Therapeutics, 1–11. doi:10.1016/j.pharmthera.2013.03.001
Wiechec, E., & Hansen, L. L. (2009). The effect of genetic variability on drug
response in conventional breast cancer treatment. European Journal of
Pharmacology, 625(1-3), 122–130. doi:10.1016/j.ejphar.2009.08.045
Yan-hong, L. I., Yong-hua, W., Yan, L. I., & Ling, Y. (2006). MDR1 Gene
Polymorphisms and Clinical Relevance. Acta Genetica Sinica , 33, 93–104.
Yusuf, S. W., Ilias-Khan, N. a, & Durand, J.-B. (2011). Chemotherapy-induced
cardiomyopathy. Expert Review of Cardiovascular Therapy, 9(2), 231–43.
Retrievedfromhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=33
22442&tool=pmcentrez&rendertype=abstract
Zhou, G., & Zhang, X. (2012). Multidrug Resistence and Breast Cancer. In R. Aft
(Ed.), Multidrug Resistence and Breast Cancer, Targeting New Pahways and
Cell Death in Breast Cancer (pp. 131–147). Shanghai: InTech. Retrieved
from www.intechopen.com
Universitas Sumatera Utara
ACS. (2011). Breast Cancer What is cancer ?(pp. 1–134).
Ambudkar, S. V, Kimchi-Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003).
P-glycoprotein: from genomics to mechanism. Oncogene, 22(47), 7468–85.
doi:10.1038/sj.onc.1206948
Amerongen, R. Van, & Berns, A. (2006). TXR1-mediated thrombospondin
repression : a novel mechanism of resistance to taxanes ? Genes &
Development, 20, 1975–1981. doi:10.1101/gad.1460806
Ameyaw M M, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. (2001).
ABCB1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is
significantly influenced by ethnicity. Pharmacogenetics, 11, 217-221
Albrektsen, G., Heuch, I. & Thoresen, S.Ø., (2010). Histological type and grade
of breast cancer tumors by parity, age at birth, and time since birth: a
register-based study in Norway. BMC cancer , 10, 226.
Ashariati, A., (2008). Polymorphism C3435T of The MDR-1 Gene Predict
Response to Preoperative Chemotherapy in Locally Advanced Breast Cancer
with Her2 / neu Expression. Acta Med Indones-Indones J Inter Med , 40(4),
187–191.
Balram, C. et al., (2003). Frequency of C3435T single nucleotide MDR1 genetic
polymorphism in an Asian population : phenotypic – genotypic correlates.
Br J Clin Pharmacol, 56, 78–83.
Bartoszek, A. (2002). Metabolic activation of adriamycin by NADPH-cytochrome
P450 reductase ; overview of its biological and. Acta Biochimica Polonica ,
49(2), 323–331.
Biemans-Oldehinkel, E., Doeven, M. K., & Poolman, B. (2006). ABC transporter
architecture and regulatory roles of accessory domains. FEBS Letters,
580(4), 1023–35
Bressolle, F., Jacquet, J., Galtier, M., Jourdan, J., & Donadio, D. (1992).
Doxorubicin and doxorubicinol plasma concentrations and excretion in
parotid saliva. Cancer Chemother Pharmacol, 30, 215–218.
Buchholz, T. a, Stivers, D. N., Stec, J., Ayers, M., Clark, E., Bolt, A., … Pusztai,
L. (2002). Global gene expression changes during neoadjuvant chemotherapy
for human breast cancer. Cancer Journal (Sudbury, Mass.), 8(6), 461–8.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12500855
Universitas Sumatera Utara
Calado, R. T., Falcao, R. P., Garcia, A. B., & Gabellini, S. M. (2002). Influence of
functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34
hematopoietic stem cells. Haematologica , 87(6), 564–568.
Callies, S., de Alwis, D. P., Wright, J. G., Sandler, A., Burgess, M., & Aarons, L.
(2003). A population pharmacokinetic model for doxorubicin and
doxorubicinol in the presence of a novel MDR modulator, zosuquidar
trihydrochloride (LY335979). Cancer Chemotherapy and Pharmacology,
51(2), 107–18. doi:10.1007/s00280-002-0542-3
Cascorbi, I. (2006). Role of pharmacogenetics of ATP-binding cassette
transporters in the pharmacokinetics of drugs. Pharmacology &
Therapeutics, 112, 457–473. doi:10.1016/j.pharmthera.2006.04.009
Chang, H., Rha, S. Y., Jeung, H., Im, C., Ahn, J. B., Kwon, W. S., … Chung, H.
C. (2008). Association of the ABCB1 gene polymorphisms 2677G > T / A
and 3435C > T with clinical outcomes of paclitaxel monotherapy in
metastatic breast cancer patients. Annals of Oncology, 2677, 1–6.
doi:10.1093/annonc/mdn624
Chargari, C., Kirov, K. M., Bollet, M. a, Magné, N., Védrine, L., Cremades, S., …
Kirova, Y. M. (2011). Cardiac toxicity in breast cancer patients: from a
fractional point of view to a global assessment. Cancer Treatment Reviews,
37(4), 321–30. doi:10.1016/j.ctrv.2010.08.007
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin
cardiomyopathy. Cardiology, 115(2), 155–62. doi:10.1159/000265166
Cizmarikova, M., Wagnerova, M., Schonova, L., Habalova, V., Kohut, A.,
Linkova, A., … Mirossay, L. (2009). MDR1 ( C3435T ) polymorphism :
relation to the risk of breast cancer and therapeutic outcome. The
Pharmacogenomics Journal, 10(1), 62–69. doi:10.1038/tpj.2009.41
Crawford, J., Dale, D. C., Lyman, G. H., & Crawford, C. N. (2004).
Chemotherapy-Induced Neutropenia, 228–237. doi:10.1002/cncr.11882
CTCAE, C. T. C. for A. E. (2010). Common Terminology Criteria for Adverse
Events ( CTCAE ). Publish (Vol. 2009, pp. 0–71). National Cancer Institute,
Cancer Therapy Evaluation Program.
Danesi, R., Fogli, S., Gennari, A., Conte, P., & Tacca, M. Del. (2002).
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline
Anticancer Drugs. Clin Pharmacokinet, 41(6), 431–444.
Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance.
Nature Reviews. Cancer , 5(4), 275–84. doi:10.1038/nrc1590
Universitas Sumatera Utara
Erdélyi, D.J. et al., (2006). The role of ABC-transporter gene polymorphisms in
chemotherapy induced immunosuppression, a retrospective study in
childhood acute lymphoblastic leukaemia. Cellular immunology, 244(2),
121–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17434155
[Accessed November 26, 2014].
Evans, T. R. J., Yellowlees, A., Foster, E., Earl, H., Cameron, D. a, Hutcheon, A.
W., … Mansi, J. L. (2005). Phase III randomized trial of doxorubicin and
docetaxel versus doxorubicin and cyclophosphamide as primary medical
therapy in women with breast cancer: an anglo-celtic cooperative oncology
group study. Journal of Clinical Oncology : Official Journal of the
American
Society
of
Clinical
Oncology,
23(13),
2988–95.
doi:10.1200/JCO.2005.06.156
Fajac, A., Gligorov, J., Rezai, K., Levy, P., Levy, E., Selle, F., … Lokiec, F.
(2010). Effect of ABCB1 C3435T polymorphism on docetaxel
pharmacokinetics according to menopausal status in breast cancer patients,
560–566. doi:10.1038/sj.bjc.6605789
Franke, R. M., Gardner, E. R., & Sparreboom, A. (2010). Pharmacogenetics of
Drug Transporters. Current Pharmaceutical Design , 16, 220–230.
Fung, K. L., & Gottesman, M. M. (2009). A synonymous polymorphism in a
common MDR1 (ABCB1) haplotype shapes protein function. Biochimica et
Biophysica Acta , 1794(5), 860–71. doi:10.1016/j.bbapap.2009.02.014
Garattini, S. (2006). Pharmacokinetics
doi:10.1016/j.ejca.2006.10.015
in
cancer
chemotherapy,
3.
Gasparini, G., Longo, R., Torino, F., Gattuso, D., Morabito, A., & Toffoli, G.
(2006). Is tailored therapy feasible in oncology ? Critical Reviews in
Oncology/Hematology, 57, 79–101. doi:10.1016/j.critrevonc.2005.07.003
Gewirtz, D. A. (1999). A Critical Evaluation of the Mechanisms of Action
Proposed for the Antitumor Effects of the Anthracycline Antibiotics
Adriamycin and Daunorubicin. Biochemical Pharmacology, 57(98), 727–
741.
Gillet, J., Efferth, T., & Remacle, J. (2007). Chemotherapy-induced resistance by
ATP-binding
cassette
transporter
genes,
1775,
237–262.
doi:10.1016/j.bbcan.2007.05.002
Gligorov, J., & Lotz, J. P. (2004b). Preclinical pharmacology of the taxanes:
implications of the differences. The Oncologist, (suppl 2), 3–8. Retrieved
from http://www.ncbi.nlm.nih.gov/pubmed/15161985
Universitas Sumatera Utara
Goldhirsch, A., Glick, J. H., Gelber, R. D., & Coates, A. S. (2001). Meeting
Highlights : International Consensus Panel on the Treatment of Primary
Breast Cancer. Journal of Clinical Oncology, 19(18), 3817–3827.
Goto, S., Ihara, Y., Urata, Y., Izumi, S., Abe, K., Koji, T., & Kondo, T. (2001).
Doxorubicin-induced DNA intercalation and scavenging by nuclear
glutathione S-transferase pi. FASEB Journal : Official Publication of the
Federation of American Societies for Experimental Biology, 15(14), 2702–
14. doi:10.1096/fj.01-0376com
Gottesman, M. M. (2002). Mechanisms of Cancer Drug Resistance.
Annu.Rev.Med,
53,
615–27.
Retrieved
from
http://www.medicine.wisc.edu/~williams/drugresistance.pdf
Gustafson, D. L., & Page, R. L. (2013). Cancer Chemotherapy. Withrow and
MacEwen’s Small Animal Clinical Oncology, 5/e (Fifth Edit., pp. 157–179).
Elsevier Inc. doi:10.1016/B978-1-4377-2362-5.00011-6
Gwak, G., Kim, J.-Y., Park, K., Shin, Y. J., Cho, H., Park, S. J., … Han, S.
(2011). Comparison of Doxorubicin plus docetaxel neoadjuvant
chemotherapy with Doxorubicin plus vinorelbine in primary breast cancer. J
Breast Cancer , 14(2), 129–34. doi:10.4048/jbc.2011.14.2.129
Huang, Y. (2007). Pharmacogenetics/genomics of membrane transporters in
cancer chemotherapy. Cancer Metastasis Reviews, 26(1), 183–201.
doi:10.1007/s10555-007-9050-6
Henderson, I.C. et al., (2003). Improved Outcomes From Adding Sequential
Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant
Chemotherapy Regimen for Patients With Node-Positive Primary Breast
Cancer. Journal of Clinical Oncology, 21(6), pp.976–983.
Ih, A. (2013). A Review on Aetio-Pathogenesis of Breast Cancer. J Genet Syndr
Gene Ther , 4(5), 1–4. doi:10.4172/2157-7412.1000142
Joerger, M., Huitema, a D. R., Meenhorst, P. L., Schellens, J. H. M., & Beijnen, J.
H. (2005). Pharmacokinetics of low-dose doxorubicin and metabolites in
patients with AIDS-related Kaposi sarcoma. Cancer Chemotherapy and
Pharmacology, 55(5), 488–96. doi:10.1007/s00280-004-0900-4
Katzung, B. (2003). Chapter 55: Cancer chemotherapy. In Basic & Clinical
Pharmacology (pp. 1281–1290).
Kimchi-sarfaty, C. et al., (2007). A “Silent” Polymorphism in the MDR1 Gene
Changes Substrate Specificity. SCIENCE , 315, pp.525–527.
Universitas Sumatera Utara
Kroetz, D.L. et al., (2003). Sequence diversity and haplotype structure in the
human ABCB1 ( MDR1 , multidrug resistance transporter ) gene.
Pharmacogenetics, 13, pp.481–494.
Kudzi, W., Dodoo, A.N.O. & Mills, J.J., (2010). Genetic polymorphisms in
MDR1 , CYP3A4 and CYP3A5 genes in a Ghanaian population : a
plausible explanation for altered metabolism of ivermectin in humans ?
BMC Medical Genetics, 11, p.111.
Lam, P. et al., (2000). The Association of Increased Weight , Body Mass Index ,
and Tissue Density with the Risk of Breast Carcinoma in Vermont.
CANCER, 89(2), pp.370–74.
Lalami, Y., Paesmans, M., Muanza, F., Barette, M., Plehiers, B., Dubreucq, L., …
Klastersky, J. (2006). Can we predict the duration of chemotherapy-induced
neutropenia in febrile neutropenic patients , focusing on regimen-specific
risk factors ? A retrospective analysis. Annals of Oncology, 17(December
2005), 507–514. doi:10.1093/annonc/mdj092
Lazo, J. S., & Schwartzt, P. E. (1985). Rapid Distribution of Adriamycin in the
Ascitic and Pleural Fluid of Women with Ovarian Carcinomas. Gynecologic
Oncology, 21, 65–72.
Lei, H., Wang, X., & Wu, C. (2012). Early stage intercalation of doxorubicin to
DNA fragments observed in molecular dynamics binding simulations.
Journal of Molecular
Graphics & Modelling, 38, 279–89.
doi:10.1016/j.jmgm.2012.05.006
Mary Ameyaw, M., & McLeod, H. L. (2006). Improving The Efficacy And Safety
Of Anticancer Agents-The Role Of Pharmacogenetics. Novel Anticancer
Agents.
McCarthy, A.R., (2006). Biological Activity of Steroid Analogues: Synthesis and
Receptor/Enzyme Interactions. University of Canterbury
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004).
Anthracyclines : Molecular Advances and Pharmacologic Developments in
Antitumor Activity and Cardiotoxicity. Pharmacol Rev, 56(2), 185–229.
doi:10.1124/pr.56.2.6.185
Monneret, C. (2001). Recent developments in the field of antitumour
anthracyclines. Eur.J.Med.Chem, 36, 483–493.
Moss, G. (1997). Breast cancer. In F. S. Bongard, M. J. Stamos, & E. Passaro
(Eds.), Surgery: A Clinical Approach (first., pp. 273–278). New York:
Churchill Livingstone.
Universitas Sumatera Utara
Morris, C. et al., 2009. Trends in Cancer Incidence , Mortality , Risk Factors ,
Health Behaviors in California. In Cancer Surveillance section . pp. 17–19.
Ostad, S. N., & Parsa, M. (2011). Breast Cancer from Molecular Point of View :
Pathogenesis and Biomarkers. In M. Gunduz & E. Gunduz (Eds.), Breast
Cancer-Focusing Tumor Microenvironment, Stem Cells and Metastasis (1st
ed., pp. 103–121). Tehran: InTech.
Oswald, S., Grube, M., Siegmund, W., & Kroemer, H. K. (2007). Transportermediated uptake into cellular compartments. Xenobiotica; the Fate of
Foreign Compounds in Biological Systems , 37(10-11), 1171–95.
doi:10.1080/00498250701570251
Panaretakis, T., Laane, E., Pokrovskaja, K., Bjo, A., Moustakas, A., Zhivotovsky,
B., … Grande, D. (2005). Doxorubicin Requires the Sequential Activation of
Caspase-2 , Protein Kinase C , and c-Jun NH 2 -terminal Kinase to Induce
Apoptosis , 16(August), 3821–3831. doi:10.1091/mbc.E04
Patel, K. J., & Tannock, I. F. (2009). The influence of P-glycoprotein expression
and its inhibitors on the distribution of doxorubicin in breast tumors. BMC
Cancer , 9, 356. doi:10.1186/1471-2407-9-356
Peterson, C., & Trouet, A. (1978). Transport and Storage of Daunorubicin and
Doxorubicin in Cultured Fibroblasts. Cancer Research, 38, 4645–4649.
Plana, J. C. (2011). Chemotherapy and the Heart. Revista Española de
Cardiología
(English
Edition),
64(5),
409–415.
doi:10.1016/j.rec.2010.12.019
Preobrazhenskaya, M. N., Tevyashova, A. N., & Olsufyeva, E. N. (2006). Second
Generation Drugs-derivatives of Natural Antitumor Anthracycline
Antibiotics Daunorubicin , Doxorubicin and Carminomycin. J Med Sci,
26(4), 119–128.
Puma, N., Ruggiero, A., Ridola, V., Ilaria, M., Giorgio, L., Stefano, A., … Rosa,
G. D. E. (2008). Anthracycline-related cardiotoxicity : risk factors and
therapeutic options in childhood cancers. SIGNAE VITAE , 3(1), 30–34.
Raisch, D. W., Holdsworth, M. T., Winter, S. S., Hutter, J. J., & Graham, M. L.
(2003). Economic Comparison of Home-Care-Based versus Hospital- Based
Treatment of Chemotherapy-Induced Febrile Neutropenia in Children. Value
in Health, 6(2), 158–166. doi:10.1046/j.1524-4733.2003.00219.x
Riddick, D. S., Lee, C., Ramji, S., Chinje, E. C., Cowen, R. L., Williams, K. J., …
Waxman, D. J. (2005). Cancer Chemotherapy And Drug Metabolism. Drug
Metabolism
and
Disposition ,
33(8),
1083–1096.
doi:10.1124/dmd.105.004374.normal
Universitas Sumatera Utara
Robert, J., Morvan, L., Smith, D., Pourquier, P., & Bonnet, J. (2005). Predicting
drug response and toxicity based on gene polymorphisms, 54, 171–196.
doi:10.1016/j.critrevonc.2005.01.005
Rowinsky, E. K. (1997). The development and clinical utility of the taxane class
of antimicrotubule chemotherapy agents. Annu.Rev.Med, 48, 353–74.
doi:10.1146/annurev.med.48.1.353
Rowinsky, E. K. (1997). The development and clinical utility of the taxane class
of antimicrotubule chemotherapy agents. Annu.Rev.Med, 48, 353–74.
doi:10.1146/annurev.med.48.1.353
Rudek, M. a, Sparreboom, A., Garrett-Mayer, E. S., Armstrong, D. K., Wolff, a
C., Verweij, J., & Baker, S. D. (2004). Factors affecting pharmacokinetic
variability following doxorubicin and docetaxel-based therapy. European
Journal of Cancer , 40(8), 1170–8. doi:10.1016/j.ejca.2003.12.026
Schimmel, K., Straaten, T. Van Der, & Bogaartz, J. (n.d.). Doxorubicin And Cpec
Induced Cardioxicity : association with the GTPase gene Rac2 , and drug
transporter genes MRP1 and MRP2.
Schwartz, J. et al., (2005). Evaluation of anemia, neutropenia and skin toxicities in
standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or
docetaxel adjuvant chemotherapy in breast cancer. Annals of oncology,
16(2), pp.247–52.
Sharom, F. J. (2008). ABC multidrug transporters : structure , function and role
in chemoresistance. Pharmacogenomics, 9, 105–127.
Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. P. (2011). Mechanisms
and management of doxorubicin cardiotoxicity. Herz, 36(4), 296–305.
doi:10.1007/s00059-011-3470-3
Simůnek, T., Stérba, M., Popelová, O., Adamcová, M., Hrdina, R., & Gersl, V.
(2009). Anthracycline-induced cardiotoxicity: overview of studies examining
the roles of oxidative stress and free cellular iron. Pharmacological Reports,
61(1),
154–71.
Retrieved
from
http://www.ncbi.nlm.nih.gov/pubmed/19307704
Sissung, T. M., Mross, K., Steinberg, S. M., Behringer, D., Figg, W. D.,
Sparreboom, A., & Mielke, S. (2006). Association of ABCB1 genotypes with
paclitaxel-mediated peripheral neuropathy and neutropenia. European
Journal Of Cancer , 42, 2893–2896. doi:10.1016/j.ejca.2006.06.017
Sledge, G.., (1999). First-Line Chemotherapy for Advancer Breast Cancer.
Journal of The Moffit Cancer Center , 6(5), pp.4–7.
Universitas Sumatera Utara
Smith, K. (2002). Genetic Polymorphism And Snps (Pp. 1–13). Retrieved From
http://grants.nih.gov
Society, A. C. (2011). Breast Cancer.
Sparreboom, A., Danesi, R., Ando, Y., Chan, J., & Figg, W. D. (2003).
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
Drug Resistance Updates, 6, 71–84. doi:10.1016/S1368-7646(03)00005-0
Sugunan, S. L. C. (2008). Pharmacogenetics Of Doxorubicin In Asian Breast
Cancer Patients. National university of Singapore.
Taheri, M., Mahjoubi, F., & Omranipour, R. (2010). Effect of MDR1
polymorphism on multidrug resistance expression in breast cancer patients.
Genet.Mol.Res, 9(1), 34–40.
Tran, A. Et Al., (2006). Pharmacogenetics And Genomics Pharmacokinetics And
Toxicity Of Docetaxel : Role Of CYP3A, MDR1, And GST
Polymorphisms. Clinical Pharmacology & Therapeutc, 79(6), Pp.570–581.
Tan, S., Lee, S., & Goh, B. (2008). Pharmacogenetics in Breast Cancer Therapy
Pharmacogenetics in Breast Cancer Therapy. Clinical Cancer Res, 14, 8027–
8041. doi:10.1158/1078-0432.CCR-08-0993
Tandon, V. R., Kapoor, B., Bano, G., Gupta, S., Gillani, Z., & Kour, D. (2006). Pglycoprotein : Pharmacological relevance relevance. Indian J Pharmacol,
38(1), 13–24.
Thorn, C., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T.,
& Altman, R. (2011). Doxorubicin pathways: pharmacodynamics and
adverse
effects.
Pharmacogenet
Genomics,
21(7),
440–446.
doi:10.1097/FPC.0b013e32833ffb56.Doxorubicin
Tsai, C., Sauna, Z. E., Kimchi-sarfaty, C., Ambudkar, S. V, Gottesman, M. M.,
Nussinov, R., & Aviv, T. (2008). Synonymous Mutations and Ribosome
Stalling Can Lead to Altered Folding Pathways and Distinct Minima.
J.Mol.Biol, 383, 281–291. doi:10.1016/j.jmb.2008.08.012
Turgut, S., Yaren, A., & Kursunluoglu, R. (2007). MDR1 C3435T Polymorphism
in Patients with Breast Cancer. Archives of Medical Research , 38, 539–544.
doi:10.1016/j.arcmed.2007.02.005
Vasiliou, V., Vasiliou, K., & Nebert, D. W. (2009). Human ATP-binding cassette
( ABC ) transporter family. Human Genomics, 3(3), 281–290.
Vávrová, A., Popelová, O., Stěrba, M., Jirkovský, E., Hašková, P., MertlíkováKaiserová, H., … Simůnek, T. (2011). In vivo and in vitro assessment of the
role of glutathione antioxidant system in anthracycline-induced
Universitas Sumatera Utara
cardiotoxicity. Archives of Toxicology, 85(5), 525–35. doi:10.1007/s00204010-0615-8
Vulsteke, C., Lambrechts, D., Dieudonné, A., Hatse, S., Brouwers, B., Brussel, T.
Van, … Wildiers, H. (2013). Genetic variability in the multidrug resistance
associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in
breast cancer patients receiving (neo-)adjuvant chemotherapy with 5fluorouracil, epirubicin and cyclophosphamide (FEC). Annals of Oncology,
1–13. doi:10.1093/annonc/mdt008
Warren, B.S. & Devine, C., (2003). Breast Cancer in Women from Different
Racial / Ethnic Groups. , (April), pp.1–5.
Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Abcb, O. (2005).
Multidrug resistance polypeptide 1 ( MDR1 , ABCB1 ) variant 3435C > T
affects mRNA stability. Pharmacogenetics and Genomics, 15, 693–704.
Westbrook, K., & Stearns, V. (2013). Pharmacology & Therapeutics
Pharmacogenomics of breast cancer therapy : An update Pharmacology and
Therapeutics, 1–11. doi:10.1016/j.pharmthera.2013.03.001
Wiechec, E., & Hansen, L. L. (2009). The effect of genetic variability on drug
response in conventional breast cancer treatment. European Journal of
Pharmacology, 625(1-3), 122–130. doi:10.1016/j.ejphar.2009.08.045
Yan-hong, L. I., Yong-hua, W., Yan, L. I., & Ling, Y. (2006). MDR1 Gene
Polymorphisms and Clinical Relevance. Acta Genetica Sinica , 33, 93–104.
Yusuf, S. W., Ilias-Khan, N. a, & Durand, J.-B. (2011). Chemotherapy-induced
cardiomyopathy. Expert Review of Cardiovascular Therapy, 9(2), 231–43.
Retrievedfromhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=33
22442&tool=pmcentrez&rendertype=abstract
Zhou, G., & Zhang, X. (2012). Multidrug Resistence and Breast Cancer. In R. Aft
(Ed.), Multidrug Resistence and Breast Cancer, Targeting New Pahways and
Cell Death in Breast Cancer (pp. 131–147). Shanghai: InTech. Retrieved
from www.intechopen.com
Universitas Sumatera Utara